Founded on a Fundamentally New Therapeutic Modality
OMEICOS Therapeutics was founded as a spin-off from the Max-Delbrück-Center (MDC) in Berlin in 2013. We have translated pioneering scientific discoveries made at the MDC in collaboration with University of Texas Southwestern Medical Center into clinical development in less than four years after founding the company. The company’s therapeutic approach targets one of nature’s most important cell-protective pathways with potential applications in cardiovascular diseases, multiple eye disorders and several other indications.
Naturally occurring metabolites of omega-3 fatty acids, so called epoxyeicosanoids, have the ability to activate anti-inflammatory, anti-arrhythmic and cardioprotective signaling cascades in human cells. These properties make them an attractive class of therapeutic candidates but due to fact that they are metabolically unstable, this potential has proven difficult to put into practice. By designing and developing stable, synthetic analogs of these epoxyeicosanoids, OMEICOS has found a way to unlock the full therapeutic potential of this approach.
OMEICOS most advanced pipeline program OMT-28 has entered a Phase 2 clinical trial in Atrial Fibrillation following very compelling safety data in mid-2018. Additionally, the company is exploring the therapeutic potential of its core approach in other cardiovascular conditions and is also advancing a number of early stage programs in several ophthalmological indications.